Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/=18 years of age~* moderate to severe rheumatoid arthritis of \>/=6 months duration~* synovitis (swollen and tender joint) in the wrist of the dominant hand~* non-biologic DMARDs at stable dose for \>/=12 weeks prior to baseline~* oral corticosteroids at stable dose for at least 25 out of 28 days prior to baseline~Exclusion Criteria:~* rheumatic autoimmune disease other than RA~* history of or current inflammatory joint disease other than RA~* functional class IV (ACR classification)~* intraarticular or parenteral corticosteroids within 6 weeks prior to baseline~* previous treatment with a biologic agent for RA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).